english English    english 中文

Win-Win Fine Chemical Expert WINWIN Chemicals

Recently, Hengrui Pharmaceutical subsidiary Shanghai Shengdi Pharmaceutical Co., Ltd. received the "Pharmaceutical Registration Certificate" issued by the State Drug Administration (NMPA) to approve the company's independent PD-L1 inhibitor Adeberley Midgrot (iResearch Profit) combined with first-line therapy for patients with Platinum and Ryposidin for patients with ES-SCLC (ES-SCLC). Adebergazab became my country's first independent R & D PD-L1 inhibitor to be approved by small cell lung cancer indications, bringing new treatment options to patients. At this point, Hengrui Pharmaceutical has been approved to be listed 12 innovative medicines.
Winwin Cheimcal news